Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase

MLA

Giovanni Orsolini, et al. “Mepolizumab 100 Mg in Severe Asthmatic Patients with EGPA in Remission Phase.” The Journal of Allergy and Clinical Immunology. In Practice, vol. 9, no. 3, May 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ac14effa025f87353dd719d45c79d82d&authtype=sso&custid=ns315887.

APA

Giovanni Orsolini, Alessandro Giollo, Matteo Maule, Ernesto Crisafulli, Giuliana Festi, Marco Caminati, Claudio Lunardi, Gianenrico Senna, & Claudio Micheletto. (2020). Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase. The Journal of Allergy and Clinical Immunology. In Practice, 9(3).

Chicago

Giovanni Orsolini, Alessandro Giollo, Matteo Maule, Ernesto Crisafulli, Giuliana Festi, Marco Caminati, Claudio Lunardi, Gianenrico Senna, and Claudio Micheletto. 2020. “Mepolizumab 100 Mg in Severe Asthmatic Patients with EGPA in Remission Phase.” The Journal of Allergy and Clinical Immunology. In Practice 9 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ac14effa025f87353dd719d45c79d82d&authtype=sso&custid=ns315887.